Supply Disruption Alert – Zyban (bupropion hydrochloride) 150mg prolonged release tablets (GlaxoSmithKline UK)

Supply Disruption Alert – Zyban (bupropion hydrochloride) 150mg prolonged release tablets (GlaxoSmithKline UK)

May 29, 2020

Department of Health and Social Care (DHSC) has issued a medicine supply disruption alert for Zyban (bupropion hydrochloride) 150mg prolonged release tablets

GlaxoSmithKline have advised that Zyban will be out of stock from week commencing 15th June 2020 until the end of November 2020. This is caused by a manufacturing site transfer.

Unlicensed supplies have been sourced.

Alternatives are available and further details can be found in the alert here.

There is currently no listing on dm+d for the imported product for prescribers to select using their prescribing systems. Where a prescriber wishes to prescribe an unlicensed import, a paper prescription should be issued as ‘Buproprion 150mg prolonged release tablets (Special Order)‘ and endorsed by the pharmacy as a non-Part VIIIB special with the following:

  • Amount dispensed over pack size used;
  • Invoice price per pack size from which the order was supplied less any discount or rebate;
  • Manufacturers’/importers’ MHRA licence number;
  • Batch number of the product supplied;
  • SP

The DHSC Medicine Supply Team provide a monthly update on potential supply issues affecting both primary and secondary care. This update is uploaded on the Specialist Pharmacy Services (SPS) website. To register, you will need  an NHS email address. Once set up and logged in, you will be able to access it online.

 



Posted in: ,


More Latest News >